ReviewInvestigational new drugs2010
Complete remission of ovarian cancer induced intractable malignant ascites with intraperitoneal bevacizumab. Immunological observations and a literature review.
Review in Investigational new drugs, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 50 citations in OpenAlex.
- Trial
- Intraperitoneal administration of cisplatin plus bevacizumab for the management of malignant ascites in ovarian epithelial cancer: results of a phase III clinical trial.Medical oncology (Northwood, London, England) · 2015Trial
- Phase II study of the combination carboplatin plus celecoxib in heavily pre-treated recurrent ovarian cancer patients.BMC cancer · 2011Trial
- Contemporary Management of Malignant Ascites.The Journal of surgical research · 2025Review
- Article
- Phase I study of intraperitoneal bevacizumab for treating refractory malignant ascites.The Journal of international medical research · 2021Article
- Bevacizumab-Based Chemotherapy Triggers Immunological Effects in Responding Multi-Treated Recurrent Ovarian Cancer Patients by Favoring the Recruitment of Effector T Cell Subsets.Journal of clinical medicine · 2019Article
- Better efficacy of intrapleural infusion of bevacizumab with pemetrexed for malignant pleural effusion mediated from nonsquamous non-small cell lung cancer.OncoTargets and therapy · 2018Article
- Observational
- The management of malignant ascites and impact on quality of life outcomes in women with ovarian cancer.Expert review of quality of life in cancer care · 2016Article
- Gastrointestinal perforation in metastatic colorectal cancer patients with peritoneal metastases receiving bevacizumab.World journal of gastroenterology · 2015Article
- Liriodenine, an aporphine alkaloid from Enicosanthellum pulchrum, inhibits proliferation of human ovarian cancer cells through induction of apoptosis via the mitochondrial signaling pathway and blocking cell cycle progression.Drug design, development and therapy · 2015Article
- Antitumor Activities of Rauwolfia vomitoria Extract and Potentiation of Carboplatin Effects Against Ovarian Cancer.Current therapeutic research, clinical and experimental · 2013Article
- Meeting the challenge of ascites in ovarian cancer: new avenues for therapy and research.Nature reviews. Cancer · 2013Article
- Thinking twice before abandoning first-line chemotherapy in ovarian cancer: report of two cases and literature review. Passing from tri-weekly to weekly regimens.International journal of clinical oncology · 2012Article
- Monoclonal antibodies in gynecological cancer: a critical point of view.Clinical & developmental immunology · 2011Review
- Immune effects of trastuzumab.Journal of Cancer · 2011Article
- Update on vaccine development for renal cell cancer.Open access journal of urology · 2010Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Malignant ascites resistant to conventional drugs frequently affects ovarian cancer patients at the end of life. Here we report the case of a patient who benefited from complete resolution of ascites after low dose intraperitoneal administration of bevacizumab. Immunological analyses showed an initial increase in proportion and function of CD8(+) effector T cells and a reduction of circulating T(reg) cells. A review of the current literature regarding bevacizumab in ovarian cancer is reported. Bevacizumab has shown a high efficacy in the treatment of ovarian cancer. Intraperitoneal administration induces an immune activation and appears promising in the treatment of malignant ascites.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.